Diagnostics for membranous nephropathy
AssigneesLe Centre National De La Recherche Scientifique, Boston Medical Center Corporation
InventorsDavid J. Salant, Laurence H. Beck, Gerard Lambeau
Life of this patent
Estimating the term…
Abstract
The invention provides immunoassays for detecting serum auto-antibodies reactive against a phospholipase A2 receptor (PLA2R) and uses thereof for diagnosis and prognosis evaluation of idiopathic membranous nephropathy (MN).
Claims22
(canceled)
(canceled)
An assay comprising measuring for antibodies that are reactive to a phospholipase A2 receptor (PLA2R) in a blood sample obtained from a patient who presents at least one symptom of idiopathic membranous nephropathy (MN) and determining if there is a detectable presence of antibodies reactive against PLA2R wherein the presence of the detectable level of antibodies indicates that the patient likely has idiopathic MN.
An assay comprising measuring for antibodies that are reactive to a phospholipase A2 receptor (PLA2R) in a blood sample obtained from a patient who previously has been successfully treated for idiopathic membranous nephropathy (MN) for determining the likelihood of relapse of idiopathic MN in the patient, and determining if there is a detectable presence of antibodies reactive against PLA2R wherein a detectable presence of antibodies reactive against PLA2R indicates that the patient likely has a relapse of idiopathic MN.
An assay comprising:
- a. measuring a level of antibodies that are reactive to a phospholipase A2 receptor (PLA2R) in a blood sample obtained from a patient who presents at least one symptom of idiopathic membranous nephropathy (MN), and
- b. comparing the measured level of the antibodies with a control data from a population of non-MN healthy individuals, wherein an increase in the antibodies that are reactive to PLA2R in the blood sample over that of the control data indicates the likelihood of idiopathic MN.
An assay comprising:
- a. measuring a level of antibodies that are reactive to a phospholipase A2 receptor (PLA2R) in a blood sample obtained from a patient who previously has been successfully treated for idiopathic membranous nephropathy (MN), and
- b. comparing the measured level of the antibodies with a control data from a population of non-MN healthy individuals, wherein an increase in the antibodies that are reactive to PLA2R in the blood sample over that of the control data indicates the likelihood of relapse of idiopathic MN.
Dependencies are inferred from the claim text.